ALMS•United States
Need professional-grade analysis? Visit stockanalysis.com
$24.98
-0.04%
End of day
Market Cap
$3.09B
P/E Ratio
N/A
Employees
221
Dividend Yield
N/A
Price Chart
Risk-Adjusted Performance
Alumis Inc (ALMS) Price Performance
Alumis Inc (ALMS) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $24.98, down 0.04% from the previous close.
Over the past year, ALMS has traded between a low of $2.80 and a high of $29.98. The stock has gained 430.4% over this period. It is currently 16.7% below its 52-week high.
Alumis Inc has a market capitalization of $3.09B.
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $22.12M
- EBITDA
- $-439,332,000
- Profit Margin
- N/A
- EPS (TTM)
- -2.15
- Book Value
- 3.69
Technical Indicators
- 52 Week High
- $30.60
- 52 Week Low
- $2.76
- 50 Day MA
- $24.84
- 200 Day MA
- $10.09
- Beta
- N/A
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 139.85
- Price/Book
- 8.04
- Enterprise Value
- $3.10B